Because of the relation between left ventricular (LV) chamber elastance and heart size, it has been hypothesized that maximum time-varying elastance (Emax) must be standardized to differentiate between preserved and depressed LV systolic performance. To test this hypothesis, we studied 66 patients, of whom 25 had a normal LV, 20 had aortic regurgitation, 14 had mitral regurgitation, and seven had cardiomyopathy, with micromanometer-determined LV pressures and radionuclide angiograms during multiple LV loading conditions. Multiple regression analysis established that Emax was independently related to LV end-diastolic volume (r= -0.69). When the Emax and LV end-diastolic volume (EDV) data from all patients were plotted, a curvilinear relation was evident. Data transformation to the base e identified two distinct linear relations, one in the normal patients of InEmax = -0.60 (InEDV) +4.34 (r= -0.67,p<0.001); and one in the patients with cardiac pathology of InEmax= -1.06(lnEDV) + 6.12 (r= -0.73, p <0.001), which differed from each other (p<0.01). When a mathematical standardization was applied to these data to eliminate the independent contribution of heart size to the reduction in InEmax, the normal patients had a standardized InEmax versus InEDV slope of 0, whereas that in the patients with cardiac pathology remained negative and continued to differ from that in the normal patients (p <0.001). Dichotomization of patients with cardiac pathology into those with preserved and depressed LV chamber elastance by InEmax or standardized InEmax provided highly concordant data (k=0.73, p <0.001). Moreover, the estimated contribution of LVEDV to the reduction in Emax in patients with cardiac pathology averaged only 14±7%. We conclude from these data that LV chamber elastance calculated with radionuclide angiography has an independent relation with LVEDV, that a mathematical standardization of Emax for heart size does not significantly alter the dichotomization of patients with cardiac pathology into those with preserved and depressed LV systolic performance, and that heart size makes a relatively small contribution to the reduction in this index of LV systolic performance. Thus, standardization for heart size may not be necessary to identify whether preserved or depressed LV chamber elastance exists in an individual adult patient with cardiac pathology compared with normal adult patients. (Circulation 1990;81:1826-1836 T he time-varying elastance concept has been shown to be relatively independent of alterations in left ventricular (LV) loading conditions but sensitive to pharmacological changes in LV contractility.1-3 Multiple studies in various animal
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Methods

Patients
The study population consisted of 66 patients, of whom 25 had atypical chest pain, who constituted the normal patient population, 20 had aortic regurgitation, 14 had mitral regurgitation, and seven had cardiomyopathy. The cardiomyopathy group consisted of two patients with LV dysfunction and interventricular conduction defects of unknown etiology, two patients with idiopathic dilated congestive cardiomyopathy, and three patients with hypertensive heart disease manifest by a history of hypertension, an increase in LV wall thickness according to echocardiography, and LV hypertrophy according to electrocardiography. This latter group, therefore, represents a hybrid group consisting of patients with either hypertrophic or dilated cardiomyopathic heart disease. There were 59 men and seven women whose ages ranged from 23 to 76 years with a mean age of 52+ 10 (SD) years for the normal patients and 54± 14 years for the patients with cardiac pathology. A cardiac catheterization was performed to evaluate atypical chest pain or to define the extent of hemodynamic impairment in the patients with valvular or cardiomyopathic heart disease. Each patient gave written, informed consent for this investigation on forms approved by the human studies committees at the University of Michigan or VA Medical Center, Ann Arbor. All patients were in normal sinus rhythm, and no patient had experienced a prior myocardial infarction or had electrocardiographic evidence of a prior myocardial infarction. Administration of all diuretics, 8-adrenergic blocking agents, and vasoactive agents was stopped 24-48 hours before the catheterization, and administration of nitrate preparations was stopped 12 hours before the catheterization. Protocol A diagnostic right and left heart catheterization documented intracardiac pressures, cardiac outputs, and normal coronary anatomy in each patient; and, in addition, normal LV size, performance, and wall motion in the normal patients and grade 3+ or 4+ angiographic regurgitation in the patients with aortic or mitral regurgitation. Each patient was then entered into the protocol, which consisted of the simultaneous acquisition of micromanometer-derived LV and ascending aortic pressures and radionuclide methoxamine or nitroprusside infusions. The infusion rates were adjusted in each patient to increase LV pressure by approximately 50 mm Hg with the vasoconstrictor and to decrease LV pressure by approximately 30 mm Hg with the vasodilator.
Hemodynamics
The hemodynamic data acquisitions have been described in detail elsewhere.14'6'7 Briefly, a right atrial pacing catheter was placed to maintain a constant heart rate throughout the protocol. A micromanometer catheter (VPC 780C or VPC 684D, Millar Instruments, Houston, Texas) was positioned to measure LV pressures (50-and 200 -mm Hg scale) and ascending aortic pressure (200 -mm Hg scale). These pressures were recorded simultaneously with two electrocardiographic leads by a physiological recorder (VR-12, Electronics for Medicine, Pleasantville, New York; Micor Siemens, Iseland, New Jersey) at 100 mm/sec for 10-20 cardiac cycles at the beginning, middle, and end of each radionuclide acquisition. These pressure waveforms were manually averaged, and the average LV pressure waveforms were hand digitalized with an inductance digitizing surface (Calcomp 9100, Anaheim, California) interfaced to a PC (IBM, Armonk, New York). A program developed in this laboratory yields instantaneous LV pressure and the first derivative of LV pressure (dP/dt) at a sampling frequency of 200 Hz from the peak of the R wave.
Echocardiographic Measurements
All patients underwent M-mode echocardiography of the LV performed at the level of the chordae tendineae. The LV dimension and wall thickness measurements were made according to American Society of Echocardiography standards.18 Then, LV mass was calculated as 1.1 [(LVEDD + PWth + IVSth)3 -(LVEDD)3], where LVEDD is LV end-diastolic diameter, PWth is posterior wall thickness, and IVSth is interventricular septal thickness.'9 These echocardiographic LV mass calculations correlate with those obtained from biplane contrast cineangiography in this laboratory (n= 19, r=0.84, p <0.001).
Radionuclide Angiography
Gated equilibrium radionuclide angiograms were acquired after in vivo red blood cell labeling with 30 mCi technetium-99m for 30-msec frames throughout the cardiac cycle for 500 cardiac cycles. During the midportion of each radionuclide acquisition, a 2-ml blood sample was drawn. The blood samples were later counted for 2 minutes, and the time delay between acquisition and counting of the blood samples was recorded. At the end of the protocol, distance measurements were made for attenuation correction. Attenuation-corrected radionuclide LV volumes were calculated frame-by-frame with background subtracted hand-drawn region-of-interest LV angiograms under control conditions and during count data, decay-corrected blood sample counts, and attenuation correction as previously validated in this laboratory.16,202'
Calculation of LV Chamber Elastance
The corresponding micromanometer LV pressures and radionuclide LV volumes for each loading condition were plotted to obtain pressure-volume loops. 16 The isochronal, instantaneous pressurevolume data points obtained during each loading condition were subjected to linear regression analysis beginning at the peak of the R wave every 30 msec for 20 sequential frames. The maximum slope was defined as Enax, which represents a relatively loadindependent measure of LV systolic performance.1-3 Validation of this radionuclide approach to calculating LV chamber elastance compared with that obtained from biplane contrast cineangiography and a representative example of the radionuclide pressure-volume loops and resultant isochrones from a normal patient have been previously published.16
Data Analysis
Methods of standardizing LV chamber elastance have been proposed.78"1422, 23 To determine the optimal variable to be used in the standardization process, a stepwise multiple regression analysis was performed in the normal patients with Emax and the input variables of body surface area, radionuclide LVEDV, body weight, and echocardiographic LV mass.
After establishing the optimal variable for standardizing Emax, we then applied a mathematical method to adjust the measured EB,, to obtain a standardized Emax: standardized Emax=mean Emax+LhEmax, where AEmax is the deviation of the measured Emax from the predicted Ema,x and the predicted Emax is obtained from Emax=m X+b. This regression equation is specified by the relation between Emax and the optimal standardizing variable in the normal patients. This mathematical method, therefore, corrects for the variation in the measured EBmax that can be attributed to the variation in X, which is the optimal standardizing variable of body or heart size. 7, 24 In an attempt to separate patients with depressed from preserved LV chamber elastance with the use of Emax and to establish whether the standardization procedure alters this dichotomization, the measured InEmax and standardized lnEmax in each patient were determined to represent depressed LV systolic performance when their LV chamber elastance fell 2 SD below the mean IlnEmax in our 25 normal patients. A Cohen's kappa test25 was then used to establish the degree of concordance between the two dichotomization procedures. In addition, a McNemar's test was used to determine whether a dissociation occurred between indexes used to identify abnormal LV systolic performance. 26 All data are presented as mean+ 1 SD. The hemodynamic data were analyzed with a repeatedmeasures analysis of variance. When a significant F stattistic was obtained, multiple-range tests were used to identify where differences occurred. A probability value of 0.05 or less was considered significant.
Results
Hemodynamics
The baseline hemodynamic data for each of the 25 normal patients and the mean baseline hemodynamic data for the four patient groups are shown in Tables 1 and 2, respectively. There was no difference between their mean heart rates. The mean LV systolic pressure in the patients with aortic regurgitation was greater than that in the normal patients (p<0.05). In the patients with mitral regurgitation, it was less than that in the patients with aortic regurgitation (p<0.05). Moreover, the mean LV enddiastolic pressure in the patients with aortic regurgitation was higher than that in the normal patients (p<O.O5). In contrast, the mean (+)dP/dtmax values did not differ significantly between the four patient groups. The mean LVEDV and LV end-systolic volumes (ESV) in the patients with aortic and mitral regurgitation were larger than those in the normal patients (p<0.05 for all comparisons), and the mean LVEDV in the patients with cardiomyopathy was less than that in the patients with aortic regurgitation (p<0.05). In the patients with aortic regurgitation, the mean ejection fraction was less than that in the normal patients (p<0.05); in the patients with cardiomyopathy, it was less than that in the normal patients and patients with aortic and mitral regurgitation (p<0.05 for all comparisons).
LV Chamber Elastance
In each patient, there was a progressive increase in the time-varying elastance throughout systole until Emax was reached.'6 The correlation coefficients for Emax ranged from 0.84 to 1.00 with a mean of 0.97± 0.03. The individual Emax values ranged from 0.18 to 7.46 mmHg/ml. The mean Emax for each patient group is shown in Table 2 . The mean Ema,, for the patients with aortic and mitral regurgitation and cardiomyopathy were all less than those in the normal patients (p<0.05 for all comparisons). Moreover, the mean Emax values for the normal patients and all patients with cardiac pathology of 5.01 +±1.52 and 1.89± 1.41 mmHg/mI, respectively, differed (p<0.001). In contrast, the extrapolated volume-axis intercepts (V0) in the normal patients and all patients with cardiac pathology of 22±18 and 40±+82, respectively, did not differ because of the wide range of values, primarily in the latter group of patients. Only one of the 25 normal patients and eight of the 41 patients with cardiac pathology had negative V, values.
Relation Between Emax and Body and Heart Size
From previous studies in animals and humans, a relation between Emax or Ees and body or LV Figure 1 ). To compensate for this curvilinear relation, these data were transformed to the base e to convert this curvilinear relation to a log linear relation of InEmax versus lnEDV. Two distinct linear relations were specified, one for the normal patients and another for the patients with cardiac pathology (Figure 2 ). For the normal patients, it was lnEmax = -0.60(lnEDV)+ 4.34 (r=-0.67, p<0.001); and for the patients with cardiac pathology, it was lnEmax=-1.06(lnEDV)+6.12 To eliminate the specific influence of heart size, as measured by radionuclide LVEDV, on these two relations, a mathematical method was used to standardize the individual lnEmax values as described in "Methods." Consequently, standardized InEmax values were obtained by adding to the mean lnEmx the deviation of the measured lnEmax from the predicted lnEmax in each patient, where the predicted lnEmax=-0.60(lnEDV)+4.34, which is specified by the relation between lnEmax and lnEDV in the As shown in Figure 3 , after this mathematical standardization, the normal patients had a standardized lnEmx versus InEDV slope of zero and a mean lnEma, of 1.56+0.24, implying that all normal patients had preserved LV chamber elastance, which fell within 2 SD of 1.56, regardless of their LVEDV. The slope of the regression line shifted upward from -1.06 to -0.46 in the patients with cardiac pathology. Nevertheless, it remained negative and continued to differ from the zero slope obtained in the normal patients (p<O.001). This suggests that residual factors existed in determining the individual values were standardized for the variation in lnEDV. As a result, the slope relating the standardized lnEm,,. to lnEDV was zero in the normal patients, suggesting that these patients all had normal left ventricular chamber elastance, irrespective of their heart size; whereas in the patients with cardiacpathology, it remained negative and different from that in the normal patients (p<O.OOJ). This suggests that additional factors provided a significant contribution to the reduction in the standardized lnEmax in thepatients with cardiacpathology. Emax, time-varying elastance; EDV, end-diastolic volume.
x Abnormal InEmx, values after the influence of heart size was removed in the patients with cardiac pathology.
Dichotomization of LV Chamber Elastance
To determine whether standardization of InEmax for heart size altered the identification of patients with cardiac pathology, who had depressed LV chamber elastance, we dichotomized these patients based on the lnEm., values obtained in the normal patient group. Depressed LV chamber elastance was defined as an lnEmax that was 2 SD below the mean lnEmax in the normal patients, whereas preserved LV chamber elastance was defined as an InEma, that remained within 2 SD of the mean lnEmax in the normal patients. Consequently, for lnEmax, depressed LV chamber elastance was specified by an InEmax that fell below 1.56-2. (0.33), or an InEma,x of less than 0.90; for standardized lnEm., depressed LV chamber elastance was defined by a standardized lnEma, that fell below 1.56-2. (0.23), or a standardized lnEma, of less than 1.08. Separation of individual patients with preserved and depressed LV chamber elastance by either the measured or standardized InEmax yielded highly concordant data (k=0.73,p<0.001, Figure 4 ). Only four patients moved from depressed to preserved and one patient from preserved to depressed LV chamber elastance after standardization of lnEma, suggesting that the measured InEmax, and standardized lnEmax values have similar discriminatory power for identifying individual patients with cardiac pathology who have depressed LV systolic performance. The dichotomization of patients with aortic regurgitation, mitral regurgitation, or cardiomyopathy into those with and without depressed LV systolic performance by the use of Em,,x (<1.97 mm Hg/ml), radionuclide LVESV (>82 ml) and ejection fraction (<45%), and (+)dP/dtmax (<1,000 mm Hg/sec) demonstrated, in general, the ability of Em to identify a greater number of patients with abnormal LV systolic performance than these other more commonly used indexes of LV systolic performance ( Figure 5 ). In patients with aortic regurgitation, 50%, 55%, 25%, and 10% (p<0.05 vs. Ema,, and ESV) were abnormal; in patients with mitral regurgitation, 64%, 50%, 14% (p<0.05 vs. Ema,x), and 14% (p<0.05 vs. Em.) were abnormal; and in patients with cardiomyopathy, 71%, 28%, 43%, and 43% were abnormal. Only in patients with aortic regurgitation were the Em. and radionuclide LVESV as frequently abnormal. In contrast, in patients with mitral regurgitation or cardiomyopathy, Em,, was more commonly abnormal than radionuclide LVESV. The Emax values were more frequently abnormal in all patient groups than were the radionuclide LV ejection fraction or (+)dP/dtma. values. . Scheme depicting dichotomization of patients with cardiac pathology into those with preserved or depressed left ventricular chamber elastance with measured InEmax or standardized lnEma,, is shown. There is a high degree of concordance, with only fourpatients changing from depressed to preserved and one patient from preserved to depressed left ventricular chamber elastance after standardization of lnEmax.
Em,,, time-varying elastance. that could be attributed to heart size. The inverse of the natural logarithm was used to assure that no negative values were involved in the calculation. For all patients with cardiac pathology and an lnEma, of less than 0.90, the percentage of depression was equal to (el56_elnE.ax)/el56; for all patients with cardiac pathology and a standardized InEmax of less than 1.08, the percentage of depression was equal to (e 5a_estandard1zed enEaxtx)eL56. Thus, the percentage of depression in lnEmax due to LVEDV was the percentage depression of lnEmax in these patients from the mean InEmax of 1.56 in the normal patients minus the percentage depression of the standardized lnEmax from the same mean. This analysis revealed that only 14±7% of the depression in Emax in the patients with cardiac pathology and depressed LV chamber elastance could be attributed to heart size.
Discussion
In physiological terms, it has been accepted that some kind of standardization for body or heart size is necessary to compare time-varying elastance determinations from mammalian species of markedly different sizes, such as rat with dog, dog with human, and human with whale, and within the same species, such as child with adult. This is because LV pressure is relatively invariate compared with LV size and stroke volume. In contrast, whether standardization of the maximum time-varying elastance (Emsx) is necessary in adult cardiology to discriminate between preserved and depressed LV systolic performance in adult patients with cardiac pathology compared with normal adult patients is not known. Furthermore, an understanding of the specific purpose for standardizing Emax is an important prerequisite. If a measure of only net LV systolic performance is desired, then Emax does not need to be standardized; but if knowledge of whether LV systolic performance is adequate for a given heart or body size is desired, then standardization of Emax for heart or body size must be considered.
The data from the present investigation address this latter issue in adult patients with and without cardiac pathology. They indicate that Emax calculated with radionuclide angiography has an independent relation with LVEDV in normal patients. A transformation of the Emax and LVEDV data to the base e made this relation linear and provided two distinctly different relations: one for the normal patients and another for the patients with cardiac pathology, which differed significantly. After a mathematical standardization, which removed the variation in lnEmax that could be accounted for by the variation in InEDV, the relation between the standardized lnEmax and heart size in the two patient groups continued to differ significantly. The dichotomization of individual patients with cardiac pathology into those with preserved and depressed LV chamber elastance by use of either the measured lnEmax or standardized lnEmax yielded highly concordant results. Furthermore, only 14% of the total decrease in lnEMiax in the patients with cardiac pathology and depressed LV chamber elastance could be attributed to heart size. Moreover, irrespective of whether Emx was standardized or not, it, in general, identified a greater proportion of patients with abnormal LV systolic performance in the three patient groups with cardiac pathology than did more commonly used indexes of LV systolic performance.
The time-varying elastance concept described by Sagawa et all and Sagawa,23 in the excised and supported LV, has been shown in animals4-6,9 and humans104",28 to be a useful index for assessing changes in LV contractility. The time-varying elastance is described by a slope (Em,,) , a volume-axis intercept (V0), and a time (Tmax). Also, Em. is relatively independent of preload and afterload,3 which makes it an especially attractive index of LV systolic performance compared with isovolumic and ejection phase indexes, which are variably affected by LV loading conditions.28- 31 Although changes in Ems,, within a given subject may reflect changes in LV contractility,10,112831 the use of Emax to identify depressed LV systolic performance in individual patients may be difficult, because heart size may introduce considerable overlap in the individual Emax values. 3, 8 Initial studies in humans attempted to index Ee, to body surface area,10"1 but the validity of such an approach has been questioned,3 and better relations between Emax and Ees and LV mass and LVEDV have been reported in normal patients.14 Consequently, other methods of standardizing Emax and Ees have been suggested. Belcher et a18 demonstrated that Ees was related to body and LV weights and that Ees could be better standardized by regression equation adjustment than by indexing. They demonstrated that a regression equation adjustment provided a better fit of these data and a reduction in the variance of the slopes, irrespective of LV contractility. Subsequently, Berko et al7 demonstrated that an inverse relation existed between Ees and LVEDV in animals under control conditions and after the production of acute mitral regurgitation. Moreover, although the LVEDV and ejection phase indexes increased after the creation of acute mitral regurgitation, Ees declined significantly. When E,, was mathematically standardized for the change in heart size, the mean standardized Ee, obtained after acute mitral regurgitation was similar to that obtained under control conditions. These data suggest that when comparisons are made before and after an intervention, which concomitantly alters heart size significantly, a standardization of this index of LV systolic performance should be performed to allow appropriate conclusions to be drawn regarding alterations in LV contractility.
Whether a similar correction is necessary to dichotomize individual patients with variable LV sizes and cardiac pathology into those with preserved and depressed LV systolic performance has not been clearly delineated. In prior studies22,23 and the present investigation, different approaches have been tried for standardizing Emax and Ees in patients with and without cardiac pathology. Originally, Suga et a122 established, in the excised supported LV, that a relation existed between Ees and the extrapolated volume-axis intercept, Vd, but not myocardial mass volume. They proposed that the simple product of E,, and Vd might be a reasonable first approach to standardizing this index of LV contractility. Subsequently, Mirsky et a123 attempted to standardize EBS beat by multiplying E,, by either V0 or LV mass volume. When they standardized EmB using V0 or LV mass, the derived parameters were found to vary between patient groups. In contrast, only four patients had a change from depressed to preserved and one patient from preserved to depressed LV chamber elastance when measured lnEmax values were compared with the standardized lnEmax values in the present investigation. Our data suggest that, in adult cardiology, alterations in LV systolic performance relative to heart size can be detected with the measured Emax, because the effect of heart size on Emax in patients with cardiac pathology is small.
There may be several possible explanations for these divergent observations. First, after an examination of the data reported by Grossman et al, 10 Suga et a122 noted that negative V0 values were common in humans, which would make the multiplication of Ees by these V0 values uninterpretable. The potential also existed in patients with large V0 and low Ees values that a simple multiplication might normalize this index in patients who clearly had depressed LV systolic performance. Moreover, if this approach is to be used, it requires that the V0 value be accurately determined. Several investigators have questioned the validity of a simple extrapolation to the volumeaxis intercept because of the estimation error that may result32 and the potential for nonlinearity of the Ees relation.23'33 Finally, in an LV, which has been altered by transient ischemia or infarction, the index of Ees multiplied by V0 may not reflect the contractile state of the residual normal myocardium. 22 Suga et a122 concluded, therefore, that this simple approach to standardization was only a first approximation and that other methods may, indeed, be necessary in humans. Accordingly, a mathematical method of standardizing Emax was used in the present investigation as a possible alternative.
The mathematical standardization of Ees used by
Berko et a17 and of Emax in the present investigation uses the linear relation between EeB or Emax and a measure of heart size to correct these slopes for the variation that can be attributed to heart size in the normal animal or human heart. This procedure corrects only the slopes and, therefore, does not depend on an extrapolation to obtain V0. In the present investigation, Emax was principally related to LVEDV, and, thus, this measure of heart size was used in the mathematical standardization. When the Emax values were standardized, no significant change occurred in the determination of whether preserved or depressed LV chamber performance was present in an individual patient with cardiac pathology. Moreover, heart size, as measured by LVEDV, contributed only 14% to the reduction in Emax in the patients with cardiac pathology and depressed LV chamber elastance. The reduction in Ees reported after the production of acute mitral regurgitation in the animals studied by Berko et a17 was approximately 20%, which is similar to that for Emax in the patients with chronic valvular derived from the stress-strain relations of a single or cardiomyopathic heart disease in the present investigation. The rightward shift in the Be, relation reported by Berko et a17 may have been a result of ventricular dilatation and remodeling and not necessarily a change in LV contractility, because the standardized Ees values were unchanged after the creation of acute mitral regurgitation. In our patients with cardiac pathology, the effects of chronic LV volume overload and cardiomyopathy may have overwhelmed these processes by producing significant depression in LV systolic performance. Consequently, in adult patients with chronic disease processes, which affect LV size and contractility, the effect of these pathophysiological processes on LV chamber elastance is substantially greater than that of heart size.
The radionuclide approach used in this investigation to calculate LV volumes and chamber elastance requires discussion. Although several methods for calculating radionuclide LV volumes have been proposed, an attenuation correction technique like that used in this investigation has been reported to provide the most accurate determination of LV volumes.213435 The radionuclide LV volume technique used in this investigation has provided LVEDV and LVESV that have correlated highly with those obtained with biplane contrast cineangiography.20,21 Moreover, it has produced comparable mean LV volumes on a frame-by-frame basis throughout the cardiac cycle to those obtained with biplane contrast cineangiography under control conditions and after alterations in LV loading conditions produced by methoxamine or nitroprusside.16 These data also show that despite the time-averaged nature and the reduced spatial and temporal resolution of radionuclide angiography compared with biplane contrast cineangiography that comparable calculations of LV chamber elastance can be obtained. 16 Thus, because the radionuclide approach does not alter LV hemodynamics, volumes, or contractility during data acquisition and because multiple acquisitions can be performed, it represents a reasonable technique for obtaining multiple pressure-volume data points to calculate LV chamber elastance in humans.
We used M-mode echocardiographic determinations of LV mass to establish the optimal measure to be used in the mathematical standardization process. We used American Society of Echocardiography criteria to measure LV dimensions and wall thicknesses in our patients, which may not be the optimal approach for calculating LV mass. 19 The biplane contrast cineangiographic calculations of LV mass used in this investigation have been previously reported to be nearly identical over a wide range of mass values to those determined at necropsy in the nonhuman primate. 36 We compared our American Society of Echocardiography and University of Pennsylvania (PENN) convention19 calculations of LV mass to these cineangiographic LV masses in patients with a wide range of LV mass calculations and found comparable correlation coefficients and similar standard errors. Despite comparable slopes in the regres-sion equations, the y axis intercepts differed. Consequently, at least in this laboratory, we assumed that an appropriate correction of either the American Society of Echocardiography or PENN convention LV mass calculations would be satisfactory for the purposes of this investigation.
We also assumed that the LV chamber elastance slopes were linear. This assumption is consistent with previous observations in animals'-6,9 and humans. [10] [11] [12] [13] [14] [15] Nevertheless, there is data to suggest that end-systolic pressure-volume relations may have a saturation effect in that they may plateau at high arterial pressures,37,38 they may become curvilinear toward the volume-axis intercept below a critical coronary perfusion pressure,39 or they may demonstrate contractiledependent curvilinearity. 40, 41 In this investigation, we did not lower arterial pressure below that reported by Sunagawa et al39 to cause curvilinearity toward the volume-axis intercept. Saturation and contractiledependent curvilinearity have not been demonstrated to occur in humans, probably because of insufficient data points. Without a greater number of data points to establish under what circumstances curvilinearity may exist in humans, it is probably reasonable, at least within the contractile ranges observed in this investigation, to assume that within the operational pressurevolume range of these LVs that the Emax relation is linear. 42 Finally, we altered LV loading conditions by steady-state infusions of methoxamine or nitroprusside with intact autonomic reflexes. To eliminate the effects of reflex changes in heart rate on LV contractility, we used right atrial pacing throughout the protocol in each patient. Although we cannot completely exclude the possibility of reflex changes in LV contractility, previous data from this laboratory would suggest that, although modest changes in catecholamines may occur, there is no significant effect on LV contractility as measured with isovolumic indexes.43 This is consistent with animal data, which suggest that greater changes in catecholamines are necessary to produce an effect on LV contractility.4445 Thus, within the modest range of loading conditions used in this investigation to calculate LV chamber elastance, there was probably little effect on basal LV contractility.
We conclude from these data that LV chamber elastance calculated with radionuclide angiography may not require standardization for heart size to establish whether LV systolic performance is preserved or depressed in an individual adult patient with LV volume overload or cardiomyopathy compared with normal adult patients. Presumably, this is because these pathological processes have a far more substantial effect on LV systolic performance than heart size, because only 14% of the reduction in Em,, in the patients with cardiac pathology and depressed LV chamber elastance in this investigation could be attributed to heart size. It would, however, appear that standardization will be necessary to determine whether an intervention significantly affects Ema or Bes, particularly when the intervention also has a significant effect on heart size.7 Moreover, it should not be concluded from the data in this investigation that a standardization of LV chamber elastance is not required to compare LV systolic performance between species.
